You are here

Article Text

Article menu
Download PDFPDF
Stomach
Original article
IRTKS is correlated with progression and survival time of patients with gastric cancer
  1. Li-Yu Huang1,2,
  2. Xuefei Wang3,
  3. Xiao-Fang Cui2,
  4. He Li3,
  5. Junjie Zhao3,
  6. Chong-Chao Wu2,
  7. Lingqiang Min3,
  8. Zhicheng Zhou4,
  9. Lixin Wan5,
  10. Yu-Ping Wang6,
  11. Chao Zhang7,8,
  12. Wei-Qiang Gao4,
  13. Yihong Sun3,
  14. Ze-Guang Han1,2
  1. 1 Key Laboratory of Systems Biomedicine (Ministry of Education) and Shanghai-MOST Key Laboratory for Disease and Health Genomics, Chinese National Human Genome Center at Shanghai, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China
  2. 2 Key Laboratory of Systems Biomedicine (Ministry of Education) and Collaborative Innovation Center of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China
  3. 3 Department of General Surgery, Zhongshan Hospital, General Surgery Research Institute, Fudan University, Shanghai, China
  4. 4 State Key Laboratory of Oncogenes and Related Genes, School of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China
  5. 5 Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
  6. 6 Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, China
  7. 7 Institute for Computational Biomedicine, Weill Cornell Medical College of Cornell University, New York, USA
  8. 8 Department of Medicine, Division of Hematology and Medical Oncology, Weill Cornell Medical College of Cornell University, New York, USA
  1. Correspondence to Yihong Sun; sun.yihong{at}zs-hospital.sh.cn and Dr. Ze-Guang Han, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, China. ; hanzg{at}sjtu.edu.cn

Abstract

Background and objectives IRTKS functions as a novel regulator of tumour suppressor p53; however, the role of IRTKS in pathogenesis of gastric cancer is unclear.

Design We used immunohistochemistry to detect IRTKS levels in 527 human gastric cancer specimens. We generated both IRTKS-deficient and p53-deficient mice to observe survival time of these mice and to isolate mouse embryonic fibroblasts (MEFs) for evaluating in vivo tumorigenicity. Co-immunoprecipitation was used to study the interaction among p53, MDM2 and IRTKS, as well as the ubiquitination of p53.

Results IRTKS was significantly overexpressed in human gastric cancer, which was conversely associated with wild-type p53 expression. Among patients with wild-type p53 (n=206), those with high IRTKS expression (n=141) had a shorter survival time than those with low IRTKS (n=65) (p=0.0153). Heterozygous p53 +/− mice with IRTKS deficiency exhibited significantly delayed tumorigenesis and an extended tumour-free survival time. p53+/− MEFs without IRTKS exhibited attenuated in vivo tumorigenicity. IRTKS depletion upregulated p53 and its target genes, such as BAX and p21. Intriguingly, IRTKS overexpression promoted p53 ubiquitination and degradation in MEFs and gastric cancer cells. Under DNA damage conditions, IRTKS was phosphorylated at Ser331 by the activated Chk2 kinase and then dissociated from p53, along with the p53-specific E3 ubiquitin ligase MDM2, resulting in attenuated p53 ubiquitination and degradation.

Conclusion IRTKS overexpression is negatively correlated with progression and overall survival time of patients with gastric cancer with wild-type p53 through promotion of p53 degradation via the ubiquitin/proteasome pathway.

  • IRTKS
  • p53
  • gastric cancer
  • ubiquitination
  • Chk2

https://doi.org/10.1136/gutjnl-2016-313478

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • L-YH, XW and X-FC contributed equally.

    • Contributors ZGH and LYH designed the experiments; LYH performed most of the animal and biochemical experiments; YS, XW, HL, JZ and LM collected and analysed patient samples; XFC, CCW and YPW performed some biochemical experiments; CZ analysed the biomedical information; LW, ZZ and WQG assisted in the analysis of some experiments. ZGH and LYH interpreted the data and wrote the manuscript.

    • Funding The study is supported from the National Natural ScienceFoundation of China (81402317, 81472621, 81672772, 81272271,81672324 and 31670806), and Science and Technology Commission ofShanghai Municipality (14ZR1429700 and 14140902500).

    • Competing interests None declared.

    • Patient consent Obtained.

    • Ethics approval Zhongshan Hospital.

    • Provenance and peer review Not commissioned; externally peer reviewed.